新型冠状病毒肺炎与5型磷酸二酯酶抑制剂
COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
作者信息
Al-Kuraishy Hayder M, Al-Gareeb Ali I, Al-Niemi Marwa S, Al-Buhadily Ali K, Al-Harchan Nasser A, Lugnier Claire
机构信息
Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Mustansiriyia University, Baghdad, Iraq.
Department of Clinical Pharmacology, Medicine and Therapeutic, Medical Faculty, College of Medicine, Al-Farahedi University, Baghdad, Iraq.
出版信息
J Microsc Ultrastruct. 2020 Dec 10;8(4):141-145. doi: 10.4103/JMAU.JMAU_63_20. eCollection 2020 Oct-Dec.
COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.
新型冠状病毒肺炎（COVID-19）的病理学主要与肺部疾病相关，这种疾病有时可能引发与炎症性疾病相关的无法控制的风暴，甚至可能致命。众所周知，5型磷酸二酯酶（PDE5）抑制剂，如西地那非，已成功用于治疗肺动脉高压；有趣的是，最近有研究表明，PDE5抑制剂可能还具有抗炎作用。因此，鉴于PDE5主要存在于肺组织和血管中，探讨使用PDE5抑制剂来克服COVID-19引发的炎症风暴是有意义的。
Zotero 插件